We Just Had An Epiphany
Tag: Biotech Stocks
🧬 Moderna (NASDAQ: MRNA) Stock Analysis: Why We Still Believe This mRNA Pioneer Is Undervalued
Moderna has already doubled from its 2025 lows, yet we believe the story is still in its early chapters. Science Day confirmed that Moderna is becoming far more than a vaccine company—it's building one of biotechnology's most ambitious programmable medicine platforms.
No Bullish Trigger: Ginkgo Bioworks Should Read “Ginkgo Bio… Doesn’t Work”
Ginkgo Bioworks (DNA) has ambitious science and flashy AI rhetoric — but declining revenues, deep losses, and no insider conviction make this a tough stock to love. 🧬📉
Funds and Analysts Love BioMarin Pharmaceutical (BMRN), A Rare Combo of Value and Growth Fighting Also Rare Genetic Diseases. Should You?
BioMarin is that rare biotech: profits, pipeline, and price discipline. VOXZOGO grows, margins expand, and catalysts stack—at a surprisingly modest valuation.